SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about appointment of senior management personnel

07 Apr 2025 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Glenmark Pharmaceuticals has informed that the Board on the recommendation of Nomination Remuneration Committee, vide Circular resolution dated April 6, 2025, has appointed Anurag Mantri as President (Senior Management Personnel) with effect from April 7, 2025. Further, it has informed that, V.S. Mani, Executive Director & Global Chief Financial Officer of the Company has conveyed his decision to opt for early retirement and has decided to step down from the position of Executive Director and Global Chief Financial Officer with effect from close of May 26, 2025. Although, for smooth transition, he has agreed to continue with the Company for some time. The candidature of Anurag Mantri to the office of Executive Director & Global Chief Financial Officer will be put up before Audit Committee, Nomination & Remuneration Committee and Board of the Company in the ensuing committee meetings/Board meeting for approval and once approved, he will then be appointed as Executive Director and Global Chief Financial Officer. The details of the aforesaid appointment and resignation as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure A. The copy of the resignation letter as received from V.S. Mani is enclosed as Annexure B.

The above information is a part of company’s filings submitted to BSE.


Glenmark Pharma Share Price

2180.65 -8.90 (-0.41%)
23-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1867.80
Dr. Reddys Lab 1301.30
Cipla 1433.10
Zydus Lifesciences 1112.10
Lupin 2356.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: